BUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the exit of its 503B sterile compounding business. 503B product sales accounted for approximately 19% of Athenex’s total product sales in the third quarter of 2022.
This Analyst Just Bumped Up Facebook Parent Meta’s Price Target By A Significant Margin – Here’s The Reason For Vote Of Confidence
Mizuho analyst James Lee maintained a Buy rating on Meta Platforms Inc (NASDAQ: META) with a
